AstraZeneca announced on Tuesday that it will invest $300 million in a facility in Rockville, Maryland, dedicated to cell therapy discovery and development.
More than 150 positions will be created at the US plant, which will first focus on producing cell treatments to enable clinical studies, according to the business, with the possibility of expanding to serve other disease areas.
“AstraZeneca and the state of Maryland have a strong commitment to innovation. “It makes us the ideal partners for this next-generation cell therapy facility,” stated Gov. Wes Moore.”This significant investment in our life sciences sector will help maintain Maryland’s leadership in the industry and sharpen our competitive edge.”
Pam Cheng, AstraZeneca’s Executive Vice President of Global Operations and IT and Chief Sustainability Officer, stated, “We are incredibly excited that more than 150 new highly skilled jobs are being created to bring our scientific work and therapies to clinical trials, which could transform the lives of patients around the world.”
said, “This new $300 million investment will accelerate our ambition to make next-generation cell therapy a reality, ensuring that we are ready to scale and meet the demands of patients.”
The new facility is located in Montgomery County’s life sciences corridor, less than five miles from one of AstraZeneca’s five global R&D facilities.
The multinational company’s portfolio includes using a person’s immune system’s T-cells to combat cancer.